November 25, 2020

Bamlanivimab EUA & Casirivimab and Imdevimab EUA
Criteria for Usage at UConn Health

Inclusion Criteria:

1. 18 years of age and older and weighing at least 40kg
2. Within 7 days of the onset of symptoms of COVID-19 from the anticipated date of bamlanivimab or casirivimab and imdevimab administration
3. Have a documented positive result of a direct SARS CoV-19 viral test (SARS-CoV-2 RNA PCR) within 5 days of the anticipated date of bamlanivimab or casirivimab and imdevimab administration

AND must meet the following clinical criteria listed below:

Group A for patients at the highest mortality risk and the number of bamlanivimab casirivimab and imdevimab doses are severely limited:

1. Patients ≥ 75 years of age
2. Patient less than 75 years of age AND have one of the following co-morbidities:
   A. Chronic Kidney Disease, Stage III or higher or receiving dialysis
   B. Congestive Heart Failure NYHA Class III or higher
   C. Severe pulmonary disease defined as one of the following:
      i. COPD with continuous home oxygen
      ii. Pulmonary hypertension or pulmonary fibrosis
      iii. Cystic fibrosis
   D. One of the following hematologic/oncologic diagnoses:
      i. S/P stem cell transplant
      ii. Active chemotherapy for acute leukemia, lymphoma, or myeloma
   E. S/P solid organ transplant
   F. Immunosuppressive therapy defined as:
      i. Receiving or have received lymphocyte depleting monoclonal antibody therapy (e.g., rituximab, ofatutumab, ocrelizumab, alemtuzumab, etc.)
   G. Parkinson’s disease

Group B if limited bamlanivimab or casirivimab and imdevimab supply available:
1. All patients included in group A
2. All Patients ≥ 65 years of age
3. Patients < 65 years of age AND have one of the following co-morbidities
   A. Diabetes mellitus (requiring medication)
   B. BMI ≥ 35

Group C if bamlanivimab or casirivimab and imdevimab supply is not limited:
1. All patients included in groups A and B
2. All patients with one of the following risk factors:
   A. Diabetes
   B. BMI ≥ 35
   C. Immunosuppressive condition or therapy not listed in group A or B
   D. Sickle cell disease
   E. ≥ 55 years of age AND have one of the following conditions:
      i. COPD or other chronic respiratory disease
      ii. Cardiovascular disease
      iii. Hypertension

Exclusion Criteria:
1. Patients hospitalized due to COVID-19
2. Patients who require oxygen therapy due to COVID-19 at the time of medication infusion to maintain oxygen saturation ≥ 94%
3. Patients who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.